Literature DB >> 32596727

Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study.

Stylianos Panopoulos1, Konstantinos Thomas1, Georgios Georgiopoulos1, Dimitrios Boumpas1, Christina Katsiari2, George Bertsias3, Alexandros A Drosos4, Kyriaki Boki5, Theodoros Dimitroulas6, Alexandros Garyfallos6, Charalampos Papagoras7, Pelagia Katsimbri1, Apostolos Tziortziotis2, Christina Adamichou3, Evripidis Kaltsonoudis4, Evangelia Argyriou5, Georgios Vosvotekas8, Petros P Sfikakis1, Dimitrios Vassilopoulos1, Maria G Tektonidou1.   

Abstract

OBJECTIVES: Evidence on comorbidity prevalence in antiphospholipid syndrome (APS) and its difference from high comorbidity burden rheumatic diseases is limited. Herein, we compare multiple comorbidities between APS and RA.
METHODS: A total of 326 patients from the Greek APS registry [237 women, mean age 48.7 (13.4) years, 161 primary APS (PAPS), 165 SLE-APS] were age/sex matched (1:2 ratio) with 652 patients from a Greek multicentre RA cohort of 3115 patients. Prevalence of cardiovascular (CV) risk factors, stroke, coronary artery disease (CAD), osteoporosis, diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), depression and neoplasms were compared between APS and RA patients using multivariate regression analysis.
RESULTS: Ηyperlipidemia and obesity (ΒΜΙ ≥ 30 kg/m2) were comparable while hypertension, smoking, stroke and CAD were more prevalent in APS compared with RA patients. Osteoporosis and depression were more frequent in APS, while DM, COPD and neoplasms did not differ between the two groups. Comparison of APS subgroups to 1:2 matched RA patients revealed that smoking and stroke were more prevalent in both PAPS and SLE-APS vs RA. Hypertension, CAD and osteoporosis were more frequent only in SLE-APS vs RA, whereas DM was less prevalent in PAPS vs RA. Hyperlipidaemia was independently associated with CV events (combined stroke and CAD) in PAPS and SLE-APS, while CS duration was associated with osteoporosis in SLE-APS.
CONCLUSION: Comorbidity burden in APS (PAPS and SLE-APS) is comparable or higher than that in RA, entailing a high level of diligence for CV risk prevention, awareness for depression and CS exposure minimization.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antiphospholipid syndrome; cardiovascular disease burden; comorbidities; depression; osteoporosis; rheumatoid arthritis

Mesh:

Year:  2021        PMID: 32596727     DOI: 10.1093/rheumatology/keaa321

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  3 in total

1.  Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.

Authors:  Eleana Bolla; Nikolas Tentolouris; Petros P Sfikakis; Maria G Tektonidou
Journal:  Lupus Sci Med       Date:  2021-12

2.  Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study.

Authors:  Maria Pappa; Maria Kosmetatou; Antonia Elezoglou; Kyriaki Boki; Pinelopi Konstantopoulou; Charalampos Papagoras; Alexandros Garyfallos; Dimitrios Vassilopoulos; Prodromos Sidiropoulos; Petros Sfikakis; Dimitrios Boumpas; George Bertsias; Maria Tektonidou; Antonis Fanouriakis
Journal:  Mediterr J Rheumatol       Date:  2022-06-30

3.  Was Antiphospholipid Syndrome a Risk Factor of Stroke? A Systemic Review and Meta-Analysis of Cohort Studies.

Authors:  Kai Zhao; Ping Zhou; Ling Xu; Ruili Li; Jincai Yang; Qiang Zhang; Mingfei Yang; Xiaoxing Wei
Journal:  Dis Markers       Date:  2021-12-16       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.